Dr. Daniel F. Hayes

Dr. Daniel F. Hayes, MD, is an internationally recognized breast medical oncologist and translational researcher specializing in biomarker development and precision oncology. He currently serves as the Stuart B. Padnos Professor of Breast Cancer Research and Professor of Internal Medicine at the University of Michigan Rogel Cancer Center. Dr. Hayes earned his medical degree from Indiana University School of Medicine, completed his residency in internal medicine at the University of Texas Southwestern Medical Center, and fellowship in hematology/oncology at Harvard’s Dana-Farber Cancer Institute. He is board-certified in Internal Medicine and Medical Oncology and is widely known for his leadership in breast cancer diagnostics and therapy.

A pioneer in the field of tumor biomarkers, Dr. Hayes has focused much of his career on developing and clinically validating circulating tumor cell assays, serum markers, and genomic tools to guide breast cancer treatment. His work helped establish guidelines for the clinical utility of HER2 testing and Oncotype DX, significantly influencing how oncologists make treatment decisions. Dr. Hayes has served as a principal investigator on multiple national trials integrating biomarkers into therapeutic strategies and has been instrumental in setting international standards for biomarker research and reporting.

Dr. Hayes has authored over 250 peer-reviewed publications and is a former President of the American Society of Clinical Oncology (ASCO), where he championed initiatives to improve evidence-based care and biomarker evaluation. He also served on the U.S. FDA’s Oncologic Drugs Advisory Committee and was the founding co-chair of the ASCO-CAP Tumor Marker Guidelines Working Group. Known as a mentor and educator, Dr. Hayes has trained many of today’s leaders in breast cancer research. Through his contributions to clinical science, policy, and mentorship, Dr. Daniel Hayes has had a lasting impact on the evolution of precision oncology in breast cancer care.